Immunoassays with novel labeled carbamazepine hapten analogues

• US 5,578,457 A
• Filed: 08/07/1992
• Issued: 11/26/1996
• Est. Priority Date: 08/07/1992
• Status: Expired due to Term

• Current Assignee: Clinical Diagnostic Systems Inc.
• Original Assignee: Johnson & Johnson Clinical Diagnostics Inc. (Johnson & Johnson)
• Inventors: Brummond, Barbara A., Ponticello, Ignazio S., Saini, Mohan S.
• Primary Examiner(s): CEPERLEY, MARY
• Application Number:
  US07/926,202
• Time in Patent Office: 1,572 Days
• Field of Search: 435/7.93, 435/188, 436/815
• US Class Current: 435/7.93
• CPC Class Codes: C07D 223/22 Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: G01N 33/535 with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
• CPC Class Codes: G01N 33/9486 Analgesics, e.g. opiates, aspirine
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds

Abstract

An immunoassay method and analytical elements for detecting carbamazepine drugs, for example, in body fluids, is described. The immunoassay method comprises:

(A) contacting a liquid sample, containing carbamazepine, with a labeled carbamazepine analogue in the presence of antibodies for carbamazepine under conditions that promote the formation of carbamazepine/antibody immunocomplexes; and

(B) determining the quantity of the drug in the liquid by measuring bound or unbound labeled drug analogue; characterized in that the labeled carbamazepine comprises:

(1) a label, of the type used in immunoassays, having an amine or sulfhydryl group;

(2) a carbamazepine nucleus; and

(3) a linking chain linking the carboxamide group of the carbamazepine nucleus to the label, said linking chain having about 4 to about 40 atoms consisting of:

(a) alkylene groups; and

(b) heterocyclic ring groups, each group being joined into the linking group through chemical groups selected from

(a) esters,

(b) amides,

(c) heteroatoms selected from --O--, --S--, and --NR--; wherein each R independently represents hydrogen or C₁ to C₆ alkyl; and

(d) carbonyl groups.

The elements of the invention are preferably dry, thin film analytical elements comprising a labeled carbamazepine analogue as described.

Claims

1. An immunoassay method for carbamazepine comprising:

A. contacting a liquid sample, containing carbamazepine, with a labeled carbamazepine analogue in the presence of antibodies for carbamazepine under conditions that promote the formation of carbamazepine/antibody immunocomplexes; and

B. determining the quantity of the drug in the liquid by measuring bound or unbound labeled drug analogue;

wherein the labeled carbamazepine analogue 1 has the structure (I);

##STR12## R represents hydrogen or lower alkyl of 1 to 6 carbon atoms R¹ is alkylene of 1 to 3 carbon atoms sufficient to form a heterocyclic group selected from 1,4-piperazinylene;

2,5-dimethyl-1,4-piperazinylene;

1,3-imidazolidinylene, and 1,4-hexahydrodiazepinylene;

R², R³, R⁴, and R⁵ each independently represent alkylene groups of 2 to 10 carbon atoms, or phenylene;

R⁷ is hydrogen or methyl;

each Z independently represents --O--, --S--, or --NR-- wherein R represents hydrogen or lower alkyl of 1 to 6 carbon atoms;

LABEL is an enzyme;

1is 0, 1 or 2;

m is 1 or 2;

n is 0, 1, or 2; and

(i) the sum of carbon and hetero atoms in the linking chain, comprising the atoms included in R², R³, R⁴, and R⁵, excluding the amide group of carbamazepine and the carbonyl group joining the label to the linking chain, is 5 to 40, (ii) provided that the bracketed components 1, m and n of structure I can appear therein in any order, and (iii) only one R², R³, R⁴, or R⁵ group can be phenylene.

2. The immunoassay method of claim 1 wherein:

R¹ represents ethylene thereby forming, with the atoms to which it is bonded, a 1,4-piperazinylene ring group;

R², R³, R⁴, and R⁵ each independently, represent methylene, ethylene, trimethylene, tetramethylene, pentylene, or hexylene; and

each Z independently represents --O--, or --NH--.

3. The immunoassay method of claim 2 wherein R¹ is ethylene, R² is tetramethylene, R³ is ethylene, propylene, or hexylene, R⁴ and R⁵ are independently ethylene, trimethylene or hexylene, R⁷ is hydrogen, Z is --O-- or --NH--.

4. The immunoassay of claim 3 wherein the label is selected from horseradish peroxidase (HRP) or amine enriched horseradish peroxidase (AHRP).

5. The method of any one of the preceding claims carried out on an immunoassay element.

6. The method of any one of claims 2-4 and 1 carried out on an immunoassay element containing the antibodies in one layer or zone and a separate layer or zone containing the labeled carbamazepine analogue.

7. The method of any one of claims 2-4 and 1 wherein the method is carried out on an immunoassay element in which the antibodies are immobilized on beads in a particulate layer and the labeled analogue is in a coating directly above the layer containing the antibodies.

8. An immunoassay element having a layer, zone or coating of a labeled carbamazepine described in any one of claims 2-4 and 1.

9. The immunoassay of any one of claims 2 to 4 wherein the labeled carbamazepine analogue is a conjugate of amine enriched horseradish peroxidase and the carbamazepine analogue N-{4-[4-(3-Succinimidoxycarbonylpropionyl)piperazinocarbonyl]butyl}carbamazepine.

11. The immunoassay of claim 5 wherein the labeled carbamazepine analogue is a conjugate of amine enriched horseradish peroxidase and the carbamazepine analogue N-{4-[4-(3-Succinimidoxycarbonylpropionyl)piperazinocarbonyl]butyl}carbamazepine.

12. The immunoassay of claim 6 wherein the labeled carbamazepine analogue is a conjugate of amine enriched horseradish peroxidase and the carbamazepine analogue N-{4-[4-(3-Succinimidoxycarbonylpropionyl)piperazinocarbonyl]butyl}carbamazepine.

13. The immunoassay of claim 7 wherein the labeled carbamazepine analogue is a conjugate of amine enriched horseradish peroxidase and the carbamazepine analogue N-{4-[4-(3-Succinimidoxycarbonylpropionyl)piperazinocarbonyl]butyl}carbamazepine.

10. An immunoassay method for carbamazepine, comprising the steps:

A. contacting a liquid sample, containing carbamazepine, with a labeled carbamazepine analogue in the presence of antibodies for carbamazepine under conditions that promote the formation of carbamazepine antibody immuno complexes;

B. applying a developing liquid to separate complexed labeled carbamazepine from uncomplexed labeled carbamazepine; and

C. determining the quantity of the drug in the liquid by measuring bound or unbound labeled drug analogue;

wherein the labeled carbamazepine analogue labeled carbamazepine analogue is a conjugate of amine enriched horseradish peroxidase and a member selected from the group consisting of N-[6-(4Succinimidoxycarbonylbutyramido)hexyl]-carbamazepine; and

N-{4-[3-(4-Succinimidoxycarbonylbutyramido)propylaminocarbonyl]butyl}carbamazepine.